TB-500
Mechanism
A lab-made fragment of thymosin beta-4, and its whole job is getting cells to move where they need to go. Cell migration, new blood vessel growth, calmer inflammation, all routed through how it handles actin inside the cell. Technical, sure. The result is tissue that heals faster.
Key Benefit
Animal studies show accelerated wound healing, cardiac repair post-MI, and reduced fibrosis. Popular in equine medicine.
Evidence Base
Multiple animal studies back it up. Zero published human RCTs, not one. Sports medicine has been running on anecdote for years now.
Route & Rationale
Subcutaneous injection. Peptide requires parenteral delivery for systemic distribution to injured tissues.
Interactions
Theoretical interaction with anticoagulants (promotes angiogenesis). No confirmed drug interactions.
Regulatory Status
Not FDA-approved. Pulled from the FDA's Category 2 list in April 2026. A PCAC review is set for July 2026. WADA already has it banned.
Cautions
Cancer (active/history)
For information and research purposes only. This is not medical advice and not a recommendation to use this substance. Discuss anything here with your healthcare provider.
